Single-cell spatial immune landscapes of primary and metastatic brain tumours.

Karimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M, Dankner M, Fallah P, Doré S, Zuo D, Fiset B, Kloosterman DJ, Ramsay L, Wei Y, Lam S, Alsajjan R, Watson IR, Roldan Urgoiti G, Park M, Brandsma D, Senger DL, Chan JA, Akkari L, Petrecca K, Guiot MC, Siegel PM, Quail DF, Walsh LA. · 2023

Read Single-cell spatial immune landscapes of primary and metastatic brain tumours. by Karimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M, Dankner M, Fallah P, Doré S, Zuo D, Fiset B, Kloosterman DJ, Ramsay L, Wei Y, Lam S, Alsajjan R, Watson IR, Roldan Urgoiti G, Park M, Brandsma D, Senger DL, Chan JA, Akkari L, Petrecca K, Guiot MC, Siegel PM, Quail DF, Walsh LA. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9931580.txt.

Introduction

Karimi and co-authors chart single-cell spatial immune landscapes in primary and metastatic brain tumors. Tumor immunity depends on cell relationships inside the tumor setting. Many single-cell studies lose that spatial context by breaking tissue apart. The team used imaging mass cytometry to keep it.

They studied 139 high-grade glioma tumors and 46 brain metastasis tumors. Analysis covered more than 1.1 million cells in 389 images. Immune layouts differed between primary tumors and metastases from varied cancers. Cell neighborhoods linked to survival in glioblastoma patients. One group, myeloperoxidase-positive macrophages, marked long-term survival. The findings show why spatial detail matters in tumor studies. They also offer new clues on brain tumor biology.

Catalog record

CREATORKarimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M, Dankner M, Fallah P, Doré S, Zuo D, Fiset B, Kloosterman DJ, Ramsay L, Wei Y, Lam S, Alsajjan R, Watson IR, Roldan Urgoiti G, Park M, Brandsma D, Senger DL, Chan JA, Akkari L, Petrecca K, Guiot MC, Siegel PM, Quail DF, Walsh LA.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE74 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9931580

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Single-cell spatial immune landscapes of primary and metastatic brain tumours By Elham Karimi, Miranda W. Yu, Sarah M. Maritan, Lucas J. M. Perus, Morteza Rezanejad, Mark Sorin, Matthew Dankner, Parvaneh Fallah, Samuel Doré, Dongmei Zuo, Benoit Fiset, Daan J. Kloosterman Published in: Nature DOI: 10.1038/s41586-022-05680-3 ABSTRACT Single-cell technologies have enabled the characterization of the tumour microenvironment at unprecedented depth and have revealed vast cellular diversity among tumour cells and their niche. Anti-tumour immunity relies on cell–cell relationships within the tumour microenvironment1,2, yet many single-cell studies lack spatial context and rely on dissociated tissues3. Here we applied imaging mass cytometry to characterize the immunological landscape of 139 high-grade glioma and 46 brain metastasis tumours from patients. Single-cell analysis of more than 1.1 million cells across 389 high-dimensional histopathology images enabled the spatial resolution of immune lineages and activation states, revealing differences in immune landscapes between primary tumours and brain metastases from diverse solid cancers. These analyses revealed cellular neighbourhoods associated with survival in patients with glioblastoma, which we leveraged to identify a unique population of myeloperoxidase (MPO)-positive macrophages associated with long-term survival. Our findings provide insight into the biology of primary and metastatic brain tumours, reinforcing the value of integrating spatial resolution to single-cell datasets to dissect the microenvironmental contexture of cancer. MAIN Brain tumours comprise a diverse repertoire of malignancies that arise either from within the brain or from cancer cells that have spread from other primary sites. The most common types of cancer representing these two classes include glioblastoma (around 50% of all primary brain malignancies in adults4) and brain metastasis (BrM) (about 90% of all brain malignancies), with BrM most frequently arising from melanoma, lung or breast tumours5. Besides surgery, cytotoxic therapies that target tumour cells—such as stereotactic radiotherapy—are often the first line of treatment, but they yield minimal benefit, with survival beyond 2 years being rare6,7. The tumour microenvironment (TME) is a major regulator of cancer progression, whose therapeutic value has grown with the advent of immune checkpoint blockade1,2. Compared with other tissues, the brain TME has a distinct composition, dominated by functionally diverse astrocytes and pro-tumorigenic macrophages that are ontogenically distinct, with the exclusion of infiltrating lymphocytes8. Many promising therapeutic targets within the TME of other cancers have been revealed by single-cell profiling technologies; for example, multiplex imaging has enabled the discovery of several new biomarkers that are predictive of outcomes and therapeutic efficacy in breast9–12, colorectal13 and pancreatic cancer14. However, comprehensive profiling of the brain TME has seen fewer (albeit important15–19) advances compared with other malignancies, and so far none have included the spatial characterization of individual cells within their niche using highly multiplexed histology. Here we use imaging mass cytometry (IMC) on patient samples to characterize the brain TME of glioblastoma and BrM, and explore how spatially resolved features relate to clinical outcomes. MAPPING THE BRAIN TME WITH IMC To comprehensively profile the cellular composition and spatial organization of the brain TME, we optimized a highly multiplexed antibody panel and IMC pipeline (Extended Data Figs. 1–3, Supplementary Figs. 1–3 and Supplementary Table 1). Antibodies were validated in normal and malignant tissues on the basis of their expected staining pattern (Extended Data Fig. 3a and Supplementary Figs. 1 and 2). We acquired 389 high-dimensional histopathology images representing 139 high-grade glioma and 46 BrM patient tumours (Fig. 1a,b and Extended Data Fig. 1a). Gliomas comprised resected tissues obtained during surgery (270 images in total, 192 from primary glioblastoma), including a subset from long-term survivors (78 images). BrM images were derived from multiple primary malignancies, including lung (51 images), breast (29 images), melanoma (19 images) and other primary sources (20 images), with patient-matched samples from the centre of the metastatic lesion (BrM-core) and tissue interface (BrM-margin). Images were segmented into 1,163,362 total cells and a supervised lineage assignment approach was used to classify tumour cells, astrocytes, blood vessels and more than 16 immune cell populations using canonical identity markers (Fig. 1c and Extended Data Figs. 1b and 2). As expected, within the stromal compartment across all tissues, major cell populations included GFAP+ astrocytes and CD68+ macrophages, whereas lymphocytes were relatively infrequent (Fig. 1d,e).Fig. 1IMC reveals cell dynamics within the brain TME.a, Schematic of the IMC pipeline applied to glioma and BrM tissue microarrays. Samples were subject to multiplex staining and data were acquired using cytometry by time-of-flight (CyTOF). Cell segmentation and lineage assignment was performed prior to spatial analysis. Created with BioRender.com. b, IMC images from glioblastoma, BrM-core and BrM-margin samples (top) and corresponding lineage assignment (bottom), with magnified regions to the right of each image. The colour codes for IMC markers (top right) and lineage assignment (bottom) are provided (representative of n = 389 images). Scale bars, 100 μm. c, Heat map showing relative average expression of all markers across cell populations identified using IMC (n = 389 images). A subset of markers was specific to the glioma IMC antibody panel (SOX2, SOX9, OLIG2, CD40, CD206; n = 270 images) and a second subset to the BrM IMC antibody panel (pan-cytokeratin, PMEL, MelanA, pERK, CIRBP; n = 119 images). d, Stacked bar graph of the indicated cell types as a percentage of all cells within the TME according to clinical subgroups. Glioma: adjacent normal (adj norm), n = 18; primary isocitrate dehydrogenase (IDH) wild type (WT), n = 192; primary IDH mutant (mut), n = 19; recurrent (recur), n = 22. BrM-core: lung, n = 29; breast, n = 17; melanoma (mel), n = 13; other, n = 13. BrM-margin: lung, n = 22; breast, n = 12; melanoma, n = 6; other, n = 7. Data are mean values; n refers to number of images. e, The distribution of cell populations as a percentage of all cells in the TME, sorted by tissue type. Cell frequencies for each image (n = 389 images) are displayed as vertical bars (colours correspond to cell lineages in b) and the associated tissue type is indicated in the horizontal panels below (colours indicated in the legend, right). Cl Mo, classical monocyte; DC, dendritic cells; Int Mo, intermediate monocyte; MG, microglia; Non-Cl Mo, non-classical monocyte; NK cells, natural killer cells; panCK, pan-cytokeratin; Tc, cytotoxic T cell; TH, T helper; Treg, T regulatory cell; other T cells, CD8−CD4− double-negative T cells. Macrophages stimulated in vitro can be defined along a continuum of activation states; although usually considered M2-like, tumour-associated macrophage activation is much more complex in situ and does not necessarily conform to the M1/M2 paradigm19,20. With this limitation in mind, we subdivided macrophages by ontogeny and activation state; expression of the purinergic receptor P2Y12 distinguished tissue-resident microglia from monocyte-derived macrophages19 (MDMs), and CD163 expression distinguished putative ‘M2-like’ from ‘M1-like’ cells21,22 (Fig. 1c and Supplementary Figs. 3, 4 and 5a). Additional pro-tumorigenic markers, including CD206 and CD39, were also enriched in the CD163+ M2-like macrophage fraction (Supplementary Fig. 5b,c). Consistent with previous reports15,16, MDMs and microglia were the dominant immune populations across all samples, comprising approximately 30.5% and 9.2% of the TME, respectively (Fig. 1d). SINGLE-CELL INTERACTION NETWORKS We quantified the frequency of each cell type as a percentage of the total number of cells within each image, and compared clinically relevant subgroups of patients (Fig. 2a,b and Supplementary Figs. 6

Read the complete text